PRIA Logo™
119-hr-727119th Congress

Prohibiting Abortion Industry’s Lucrative Loopholes Act

Sponsored By: Representative Franklin, Scott [R-FL-18]

Introduced

Summary

Broadening what counts as “valuable consideration” for human fetal tissue. This bill would amend the Public Health Service Act to list six specific categories of payments and in-kind benefits that qualify as valuable consideration for fetal tissue transactions.

Show full summary
  • Researchers and research institutions would see more types of financial and nonfinancial exchanges treated as valuable consideration, so payments tied to obtaining or handling fetal tissue could trigger prohibitions or enforcement.
  • Hospitals, labs, transporters, and service providers that handle fetal tissue would be directly affected because the bill explicitly covers gifts, waived fees, canceled debt, transfers of items, and payments for transportation, processing, preservation, quality control, or storage.
  • Federal regulators and prosecutors would have a broader legal definition to use when examining or pursuing improper sales or transactions involving human fetal tissue.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 0 benefits, 1 costs, 0 mixed.

Tighter rules on fetal tissue payments

If enacted, this bill would expand what counts as a payment tied to human fetal tissue. It would include cash payments, gifts or honoraria, waived or reduced fees, canceled loans, transfers of items or services given for free or at reduced cost, and payments for transport, processing, storage, or quality control. That broader definition would make more kinds of transfers subject to prohibitions or enforcement. Researchers, hospitals, tissue banks, and labs could face more legal and compliance risk. The change would take effect upon enactment.

Sponsors & CoSponsors

Sponsor

Franklin, Scott [R-FL-18]

FL • R

Cosponsors

  • Rep. Weber, Randy K. Sr. [R-TX-14]

    TX • R

    Sponsored 1/24/2025

  • Rep. Van Duyne, Beth [R-TX-24]

    TX • R

    Sponsored 1/24/2025

  • Rep. Gosar, Paul A. [R-AZ-9]

    AZ • R

    Sponsored 1/24/2025

  • Rep. Self, Keith [R-TX-3]

    TX • R

    Sponsored 1/24/2025

  • Rep. Rogers, Harold [R-KY-5]

    KY • R

    Sponsored 1/24/2025

  • Rep. Ellzey, Jake [R-TX-6]

    TX • R

    Sponsored 1/24/2025

  • Rep. Miller, Mary E. [R-IL-15]

    IL • R

    Sponsored 1/24/2025

  • Rep. Babin, Brian [R-TX-36]

    TX • R

    Sponsored 1/24/2025

  • Rep. Rutherford, John H. [R-FL-5]

    FL • R

    Sponsored 1/24/2025

  • Rep. Webster, Daniel [R-FL-11]

    FL • R

    Sponsored 1/24/2025

  • Rep. Moolenaar, John R. [R-MI-2]

    MI • R

    Sponsored 1/24/2025

  • Rep. Biggs, Sheri [R-SC-3]

    SC • R

    Sponsored 4/8/2025

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation